Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zura Bio LtdZURA · Entity 5413 | See Remarks | April 22, 2024 | September 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zura Bio Ltd
Report date April 22, 2024 · Filed September 06, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | IndirectBy corporation | 7,987 |
Reported balance
After 2024-04-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-04-22 · Grant · Acquired 7,987 · Balance 7,987 F1: On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'. F2: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share. F3: These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'.
F2: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share.
F3: These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jun 21, 2024 22:11 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001415889-24-017865 · form4-06212024_100652.xml · derivative · entry 1 Howell Michael · CIK 0001970231 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,000 Underlying: Class A Ordinary Shares · 295,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on June 18, 2025, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 18, 2024 Filed Aug 8, 2024 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | Tax withholdingClass A ordinary shares | 9,860 | $6.05 | $59,653.00 |
DisclosureSEC source: 0001415889-24-020979 · form4-08082024_040801.xml · nonDerivative · entry 1 Howell Michael · CIK 0001970231 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,535 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 22:54 UTC | Zura Bio Ltd ZURA · Entity 5413 | PurchaseClass A ordinary shares | 7,987 | $3.13 | $24,999.31 |
DisclosureSEC source: 0001415889-24-011482 · form4-04242024_100418.xml · nonDerivative · entry 1 Howell Michael · CIK 0001970231 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By corporation Disclosed balance after: 7,987 F1 · kind: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share. F2 · ownership.nature: These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 22, 2024 Filed Sep 6, 2024 21:31 UTC Amendment | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A ordinary shares | 7,987 | $3.13 | $24,999.31 |
DisclosureSEC source: 0001415889-24-023026 · form4a-09062024_090901.xml · nonDerivative · entry 1 Howell Michael · CIK 0001970231 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By corporation Disclosed balance after: 7,987 F1 · kind: On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'. F2 · shares: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share. F3 · ownership.nature: These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:17 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A Ordinary Shares | 114,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-063316 · tm2316481-5_4seq1.xml · nonDerivative · entry 1 Howell Michael · CIK 0001970231 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,395 F1 · shares: The Reporting Person was granted an award of 114,395 Restricted Share Units ("RSUs") on May 18, 2023 (the "Grant Date"). Under the terms of the RSU grant, 25% of the RSUs vest on each of the anniversaries of the Grant Date, such that the RSUs vest equally over four years, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.